

PHEBRA COMMENCES VALIDATION MANUFACTURING AT NEW PLANT

The Australian pharmaceutical firm, Phebra, has now occupied the new building and commenced the first stage of validation manufacturing at its new plant at Lane Cove West, Chief Executive Officer, Dr Mal Eutick, said today.

Dr Eutick said the manufacture of the first of a series of validation batches of Phebra's wide range of medicines commenced this week in preparation for the plant's planned inspection and licensing by the Therapeutic Goods Administration (TGA).

"It is a credit to our General Manager, Andre Vlok and his staff, including external consultants, who have planned and worked so intensively for over 18 months to bring this project to this stage - it's a wonderful Christmas present for all concerned," Dr Eutick said today.

"The products being manufactured will eventually cover Phebra's full range of critical medicines, including emergency injectables, antidotes and other small volume injections."

Dr Eutick said the manufacture of validation batches enabled Phebra experts to successfully operate the new multi-million dollar Bosch integrated filling machine inside the plant's multi-purpose sterile injectables unit.

"Phebra is excited that product validation has commenced and that once a TGA manufacturing licence for the new facility has been granted, we will be able to enhance our capacity to manufacture critical medicines for the local Australian and New Zealand markets as well as export markets," Dr Eutick explained.

"Furthermore, the extra rate of production will expand Phebra's capacity and capability to conduct all-important research programs, now and into the future."

ABOUT PHEBRA

Phebra is an Australian specialty pharmaceutical company that develops manufactures and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

The company's critical medicines cover a range of pharmaceuticals in important disease areas such as cystic fibrosis, antidotes, diagnostics, oncology and pain.

At Phebra, we create critical medicines that save and improve lives.



Above: Validation manufacturing undertaken at the new Phebra plant.

MEDIA CONTACT:
Richard Lenarduzzi at the The Premier Communications Group
+61 2 92473337 info@premiercomms.com.au